Turning Point Therapeutics Announces 2021 Milestone Targets
Turning Point Therapeutics (TPTX) announced significant milestones for 2021, including updated data from the TRIDENT-1 study on ROS1-positive non-small cell lung cancer, scheduled for January 31 at the World Conference on Lung Cancer. The company plans to submit its fourth drug candidate IND in Q1 and initiate combination studies for repotrectinib and TPX-0022. As of December 31, 2020, it holds approximately $1.1 billion in cash to fund operations into 2024. The CEO expressed confidence in advancing their pipeline amid regulatory feedback.
- Approximately $1.1 billion in cash expected to fund operations into 2024.
- Updated data from TRIDENT-1 study will be presented on January 31.
- Initiation of multiple new clinical studies planned for 2021.
- Broadening collaboration with Zai Lab for TPX-0022 licensing in China.
- Dependence on regulatory feedback for advancing clinical trials.
- Potential risks associated with the efficacy and safety of drug candidates.
- Present Updated Data from TRIDENT-1 Study in TKI-Naive Patients with ROS1-Positive Non-Small Cell Lung Cancer Jan. 31 at World Conference on Lung Cancer
- Provide TRIDENT-1 Study Timeline in First Quarter
- Provide Clinical Data Interim Updates from Multiple Studies, including Phase 1/2 TRIDENT-1, Phase 1 SHIELD-1 and Phase 1 Study of TPX-0046
- Submit Fourth Drug Candidate IND in First Quarter
- Initiate Combination Studies for Repotrectinib and TPX-0022
- Outline Precision Therapy Research Vision in Second Half
- Company also Updates Cash, Cash Equivalents, and Marketable Securities as of Dec. 31, 2020; Approximately
$1.1 Billion Expected to Fund Current Operations into 2024
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced 2021 milestone targets for its pipeline of four drug candidates, including data updates from multiple clinical studies and the initiation of new clinical studies. The company also updated its cash position as of Dec. 31, 2020.
“Following a pivotal year in 2020, we believe we have even greater opportunities in 2021 to further advance our pipeline by potentially modifying our SHIELD-1 study to a registrational Phase 1/2 design, adding three new clinical trials, including two anticipated combination studies and a Phase 1 study of our fourth drug candidate, our novel ALK-inhibitor TPX-0131, and reporting initial or updated data from our three clinical stage drug candidates,” said Athena Countouriotis, M.D., president and chief executive officer. “At the same time, we have continued to invest in our discovery engine and look forward to the second half of the year when we plan to outline our focus and goals to further expand the pipeline.”
2020 Achievements and 2021 Milestone Targets
Repotrectinib, ROS1 and TRK Inhibitor
In 2020, repotrectinib was granted breakthrough-therapy designation (BTD) and received its second and third fast-track designations. In addition, the company signed an exclusive license agreement with Zai Lab to develop and commercialize repotrectinib in greater China and reported early interim data from the Phase 2 TRIDENT-1 registrational study.
2021 Milestone Targets:
- Present updated data from the TRIDENT-1 study in TKI-naive patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) in a mini-oral presentation on Jan. 31 at the World Conference on Lung Cancer
- Provide an update on the overall Phase 2 TRIDENT-1 registrational study timeline in the first quarter
- Initiate the Phase 2 TRIDENT-2 combination study in patients with KRAS mutant NSCLC mid-year
- Provide clinical data updates from certain cohorts of the Phase 2 TRIDENT-1 study in the second half
TPX-0022, MET/SRC/CSF1R Inhibitor
In 2020, Turning Point advanced its clinical development of TPX-0022 and reported initial data from the Phase 1 SHIELD-1 study in an oral presentation during the plenary session at the EORTC-NCI-AACR medical symposium.
Earlier today, the company announced the broadening of its collaboration with Zai Lab to include an exclusive licensing agreement for TPX-0022 in greater China.
2021 Milestone Targets:
- Initiate the Phase 2 portion of SHIELD-1, pending FDA feedback, in the second half
- Initiate the Phase 2 SHIELD-2 study of TPX-0022 in combination with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor in the second half
- Provide a clinical data update from the Phase 1 portion of the SHIELD-1 study in the second half
TPX-0046, RET Inhibitor
In 2020, Turning Point presented preclinical data highlighting the potent inhibition of TPX-0046 against wildtype RET and RET mutations, and continued its ongoing Phase 1 study of TPX-0046.
2021 Milestone Target:
- Report early interim data from initial patients enrolled in the dose finding portion of the TPX-0046 Phase 1 study in the first half
TPX-0131, ALK Inhibitor
In 2020, Turning Point nominated TPX-0131 as its ALK inhibitor drug candidate, advanced its IND enabling studies, and presented preclinical data highlighting its ability to overcome ALK resistant mutations refractory to approved ALK inhibitors.
2021 Milestone Targets:
- Submit the IND for TPX-0131 in the first quarter
- Initiate a Phase 1 clinical study of TPX-0131 in the first half
Early Discovery Pipeline
In 2020, Turning Point named Siegfried Reich as chief scientific officer and made investments to advance its research strategy.
2021 Milestone Target:
- Outline research strategy, focus and milestones for future development candidates in the second half
Financial
In 2020, Turning Point completed follow-on stock offerings generating gross proceeds of
About Turning Point Therapeutics Inc.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study called TRIDENT-1 in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is in a Phase 1 study called SHIELD-1 in patients with advanced or metastatic solid tumors harboring genetic alterations in MET; RET-inhibitor TPX-0046, which is in a Phase 1/2 study of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and ALK-inhibitor TPX-0131, which is in IND-enabling studies. Turning Point’s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Turning Point Therapeutics’ drug candidates repotrectinib, TPX-0022, TPX-0046 and TPX-0131, the results, conduct, progress and timing of Turning Point Therapeutics’ research and development programs and clinical trials including the Phase 2 TRIDENT-1 clinical study, the Phase 1 SHIELD-1 clinical study of TPX-0022 and the Phase 1/2 clinical study of TPX-0046, plans regarding future clinical trials and regulatory submissions, the regulatory approval path for repotrectinib, and the strength of Turning Point Therapeutics’ balance sheet and the adequacy of cash on hand. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans”, “will”, “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics’ business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point’s business and the other risks described in Turning Point Therapeutics’ filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contact:
Jim Mazzola
jim.mazzola@tptherapeutics.com
858-342-8272
FAQ
What are the key milestones for TPTX in 2021?
How much cash does Turning Point Therapeutics have as of December 31, 2020?
What collaboration has TPTX expanded in 2021?
When will updated data from the TRIDENT-1 study be presented?
